Taysha Gene Therapies (NASDAQ:TSHA) Price Target Cut to $7.00 by Analysts at Piper Sandler

Taysha Gene Therapies (NASDAQ:TSHA) had its price target cut by Piper Sandler from $9.00 to $7.00 in a research note published on Monday, Benzinga reports. They currently have an overweight rating on the stock.

TSHA has been the topic of several other research reports. JMP Securities reaffirmed a market outperform rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Chardan Capital reissued a buy rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, June 18th. Canaccord Genuity Group restated a buy rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Needham & Company LLC restated a buy rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, June 17th. Finally, Cantor Fitzgerald restated an overweight rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of Buy and an average price target of $6.60.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $2.15 on Monday. The stock’s fifty day moving average is $2.96 and its two-hundred day moving average is $2.43. The firm has a market capitalization of $402.09 million, a P/E ratio of -4.39 and a beta of 0.42. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38. Taysha Gene Therapies has a fifty-two week low of $0.61 and a fifty-two week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. The company had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. On average, research analysts anticipate that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning purchased 1,333,333 shares of Taysha Gene Therapies stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the transaction, the insider now directly owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of TSHA. Schonfeld Strategic Advisors LLC acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $2,275,000. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $4,740,000. Kynam Capital Management LP acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $10,369,000. RTW Investments LP acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $53,382,000. Finally, RA Capital Management L.P. acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $58,373,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.